Get started
INVENTISBIO CO LTDII

INVENTISBIO CO LTD

31.23CNYD
−0.53−1.67%
As of today at 02:31 GMT
CNY
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

688382 fundamentals

Key facts

Market capitalization‪17.81 B‬CNY
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.37CNY
Founded2013
Employees (FY)185
CEOYao Lin Wang
Websiteinventisbio.com
About

InventisBio, Co., Ltd. engages in drug research and development focusing on major diseases such as tumors and metabolic diseases. Its drugs have been developed to cover solid tumors such as non-small cell lung, breast, and colorectal cancer, as well as metabolic diseases such as hyperuricemia and gout. The company was founded by Yaolin Wang on January 11, 2013 and is headquartered in Shanghai, China.

Ownership
‪‪401.30 M‬‬
Free Float shares
‪‪372.40 M‬‬ (92.8%)
Closely held shares
‪‪28.90 M‬‬ (7.2%)
Free Float shares
‪‪372.40 M‬‬ (92.8%)
Closely held shares
‪‪28.90 M‬‬ (7.2%)
Capital structure
Market cap
‪‪17.81 B‬‬
Debt
‪‪22.87 M‬‬
Cash & equivalents
‪‪1.63 B‬‬
Enterprise value
‪‪16.20 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪17.81 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
105.57x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
105.57x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪20.00‬
‪40.00‬
‪60.00‬
‪80.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,400.0%‬
‪−1,600.0%‬
‪−800.0%‬
‪0.0%‬
‪800.0%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−160.00 M‬‬
‪‪−80.00 M‬‬
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−75.00 M‬‬
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−60.00 M‬‬
‪‪−40.00 M‬‬
‪‪−20.00 M‬‬
‪0.00‬
‪‪20.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Innovative Drugs
By country
Period: 2024
China

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪2.00 M‬‬
‪‪4.00 M‬‬
‪‪6.00 M‬‬
‪‪8.00 M‬‬
Actual
Earnings
Next:Apr 27, 2026
2022
2023
2024
2025
‪−1.00‬
‪−0.75‬
‪−0.50‬
‪−0.25‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
688382 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−700.00 M‬‬
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
‪‪2.00 B‬‬
Assets
Liabilities